OBJECTIVES: To determine the percentages of patients who discontinued treatment with the multiple sclerosis medications intramuscular interferon beta-1a (IFN-beta-1a; Avonex-Biogen), interferon beta-1b (IFN-beta-1b; Betaseron-Berlex), and glatiramer acetate (Copaxone-Teva) and to determine the factors that led to discontinuation of the medications. DESIGN: Cross-sectional study. SETTING: University-based neurology clinic. PATIENTS: 108 patients with multiple sclerosis who were prescribed intramuscular interferon beta-1a, subcutaneous interferon beta-1b, or subcutaneous glatiramer acetate. INTERVENTION: Telephone survey. MAIN OUTCOME MEASURES: Discontinuation percentages and the factors that contributed to discontinuation. RESULTS: There was no significant difference between the percentages of patients who discontinued and did not restart treatment with the products (interferon beta-1b, 41%; intramuscular interferon beta-1a, 34%; and glatiramer acetate, 28%). Four main reasons for medication discontinuation emerged: adverse effects (52%), physician-documented disease progression (40%), patient perception of drug ineffectiveness (20%), and cost (4%). No statistical differences were identified among the three agents for any of the reasons for discontinuation. CONCLUSION: Patient education on adverse effects and realistic patient expectations may be potential areas of study to improve discontinuation percentages with these agents.
OBJECTIVES: To determine the percentages of patients who discontinued treatment with the multiple sclerosis medications intramuscular interferon beta-1a (IFN-beta-1a; Avonex-Biogen), interferon beta-1b (IFN-beta-1b; Betaseron-Berlex), and glatiramer acetate (Copaxone-Teva) and to determine the factors that led to discontinuation of the medications. DESIGN: Cross-sectional study. SETTING: University-based neurology clinic. PATIENTS: 108 patients with multiple sclerosis who were prescribed intramuscular interferon beta-1a, subcutaneous interferon beta-1b, or subcutaneous glatiramer acetate. INTERVENTION: Telephone survey. MAIN OUTCOME MEASURES: Discontinuation percentages and the factors that contributed to discontinuation. RESULTS: There was no significant difference between the percentages of patients who discontinued and did not restart treatment with the products (interferon beta-1b, 41%; intramuscular interferon beta-1a, 34%; and glatiramer acetate, 28%). Four main reasons for medication discontinuation emerged: adverse effects (52%), physician-documented disease progression (40%), patient perception of drug ineffectiveness (20%), and cost (4%). No statistical differences were identified among the three agents for any of the reasons for discontinuation. CONCLUSION:Patient education on adverse effects and realistic patient expectations may be potential areas of study to improve discontinuation percentages with these agents.
Authors: Stephanie C Steinberg; Richard J Faris; Cyril F Chang; Andrew Chan; Mark A Tankersley Journal: Clin Drug Investig Date: 2010 Impact factor: 2.859
Authors: Richard Nicholas; Paolo Giannetti; Ali Alsanousi; Tim Friede; Paolo A Muraro Journal: Drug Des Devel Ther Date: 2011-05-10 Impact factor: 4.162
Authors: Mohammed Aljumah; Raed Alroughani; I Alsharoqi; Saeed A Bohlega; Maurice Dahdaleh; Dirk Deleu; Khaled Esmat; Ahmad Khalifa; Mohammad A Sahraian; Miklós Szólics; Abdulrahman Altahan; Bassem I Yamout; Peter Rieckmann; Abdulkader Daif Journal: Mult Scler Int Date: 2013-12-17
Authors: Christoph Kleinschnitz; Gabriele Niemczyk; Karin Rehberg-Weber; Colin Wernsdörfer Journal: Int J Mol Sci Date: 2015-07-06 Impact factor: 5.923